## APPENDIX E. FOREST PLOTS

Forest plots below represent efficacy findings in terms of Hedges' g for each intervention. Within each plot, results are presented both by migraine type and overall (representing each migraine type filter option from the visualization). Each data point represents the longest follow-up timepoint reported in the study (consistent with the "Any" option for follow-up in the visualization). An asterisk (\*) next to a study name indicates that the study reported results, but reporting was insufficient for inclusion in the meta-analysis.

Figure E-1. Amitryptiline




Figure E-2. Atopegant




Figure E-3. Candesartan




Figure E-4. Eptinezumab

Intervention: Eptinezumab					
Migraine Type	Risk of			Hedges' g	%
and Study Name	bias			(95% CI)	Weight
Chronic					
Lipton 2020	Low		<b>*</b>	0.40 (0.28, 0.53)	47.87
Subgroup (I-squared = .%)			<b> </b> •	0.40 (0.28, 0.53)	47.87
Episodic					
Ashina 2020	Unclear		*	0.28 (0.13, 0.44)	33.42
Subgroup (I-squared = .%)			$\Diamond$	0.28 (0.13, 0.44)	33.42
NR/Other					
Dodick 2019	Low		<del>+</del>	0.30 (0.09, 0.50)	18.70
Subgroup (I-squared = .%)			$\Diamond$	0.30 (0.09, 0.50)	18.70
Heterogeneity between groups: p = 0.43	6				
Overall (I-squared = 0.0%)			◊	0.34 (0.26, 0.43)	100.00
	-4	Face leasting	0	4	
NOTE: Weights are from random-effects model		Favors Inactive	Favors Eptinezumab		

Figure E-5. Erenumab




Figure E-6. Fremanezumab




Figure E-7. Galcanezumab




Figure E-8. Lisinopril




Figure E-9. Metoprolol




Figure E-10. Non-invasive Vagal Nerve Stimulation




Figure E-11. OnabotulinumtoxinA




Figure E-12. Propanolol




Figure E-13. Topiramate




Figure E-14. Transcutaneous Supraorbital Nerve Stimulation




Figure E-15. Valproic Acid/Valproate




Figure E-16. Venlafaxine

